A phase 3 BASIS analysis examined the use of factor replacement therapy for breakthrough bleeds and the perioperative management of minor and dental procedures among patients receiving marstacimab...
The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...
A phase 3 randomized trial found that Mim8 prophylaxis significantly reduced bleeding rates compared with on-demand therapy and clotting factor prophylaxis in patients with hemophilia A with or without...
The FDA has approved concizumab-mtci, a daily subcutaneous treatment to reduce bleeding for patients with hemophilia who have clotting factor inhibitors.
The FDA has approved a novel therapy for patients with hemophilia A or B without inhibitors. Clinical trials showed it significantly reduces bleeding episodes by targeting a new protein in the blood...
After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.
Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with meningitis B, hemophilia A, and non-valvular atrial fibrillation.
